HARBIN, China, Jan. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has relocated its headquarters to its new buildings in the Harbin Song Bei New Development district to better accommodate the Company's significant growth.
China Sky One Medical completed this first phase of construction in December 2009. The Company's two new six-story buildings cost approximately $13 million and will accommodate administration, research and development, accounting, and sales functions. Management believes that combining its operations into one centralized location will result in greater efficiency and make it easier to conduct business.
The Company's new address is No. 2158, North Xiang An Road, Song Bei District, Harbin, Heilongjiang Province, P. R. of China 150028. The main contact number at the Company is 86-451-8703-2617.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include expectations of future growth or information regarding the move to new headquarters. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Stanley Hao, CFO Tel: +86-0451-8703-2617 Email: firstname.lastname@example.org Investor Relations Contact: CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: email@example.com Web: http://www.ccgirasia.com Mr. R. Micchelli, Sr. Financial Writer Tel: +1-646-454-4516 Email: firstname.lastname@example.org
SOURCE China Sky One Medical, Inc.
|SOURCE China Sky One Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved